Literature DB >> 30385580

Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin.

Nick S Laursen1, Robert H E Friesen2, Xueyong Zhu1, Mandy Jongeneelen3, Sven Blokland3, Jan Vermond4, Alida van Eijgen4, Chan Tang3, Harry van Diepen4, Galina Obmolova2, Marijn van der Neut Kolfschoten3, David Zuijdgeest3, Roel Straetemans5, Ryan M B Hoffman1, Travis Nieusma1, Jesper Pallesen1, Hannah L Turner1, Steffen M Bernard1, Andrew B Ward1, Jinquan Luo2, Leo L M Poon6, Anna P Tretiakova7, James M Wilson7, Maria P Limberis7, Ronald Vogels3, Boerries Brandenburg3, Joost A Kolkman8, Ian A Wilson9,10.   

Abstract

Broadly neutralizing antibodies against highly variable pathogens have stimulated the design of vaccines and therapeutics. We report the use of diverse camelid single-domain antibodies to influenza virus hemagglutinin to generate multidomain antibodies with impressive breadth and potency. Multidomain antibody MD3606 protects mice against influenza A and B infection when administered intravenously or expressed locally from a recombinant adeno-associated virus vector. Crystal and single-particle electron microscopy structures of these antibodies with hemagglutinins from influenza A and B viruses reveal binding to highly conserved epitopes. Collectively, our findings demonstrate that multidomain antibodies targeting multiple epitopes exhibit enhanced virus cross-reactivity and potency. In combination with adeno-associated virus-mediated gene delivery, they may provide an effective strategy to prevent infection with influenza virus and other highly variable pathogens.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30385580      PMCID: PMC6241527          DOI: 10.1126/science.aaq0620

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  46 in total

1.  Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking.

Authors:  Toshihiko Ogura; Kenji Iwasaki; Chikara Sato
Journal:  J Struct Biol       Date:  2003-09       Impact factor: 2.867

Review 2.  Single-domain antibodies for biomedical applications.

Authors:  Simon Krah; Christian Schröter; Stefan Zielonka; Martin Empting; Bernhard Valldorf; Harald Kolmar
Journal:  Immunopharmacol Immunotoxicol       Date:  2015-11-09       Impact factor: 2.730

3.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

4.  Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered.

Authors:  Maria P Limberis; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-22       Impact factor: 11.205

5.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

Authors:  Anna Hultberg; Nigel J Temperton; Valérie Rosseels; Mireille Koenders; Maria Gonzalez-Pajuelo; Bert Schepens; Lorena Itatí Ibañez; Peter Vanlandschoot; Joris Schillemans; Michael Saunders; Robin A Weiss; Xavier Saelens; José A Melero; C Theo Verrips; Steven Van Gucht; Hans J de Haard
Journal:  PLoS One       Date:  2011-04-01       Impact factor: 3.240

8.  H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps.

Authors:  Hang Xie; Xiu-Feng Wan; Zhiping Ye; Ewan P Plant; Yangqing Zhao; Yifei Xu; Xing Li; Courtney Finch; Nan Zhao; Toshiaki Kawano; Olga Zoueva; Meng-Jung Chiang; Xianghong Jing; Zhengshi Lin; Anding Zhang; Yanhong Zhu
Journal:  Sci Rep       Date:  2015-10-16       Impact factor: 4.379

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  64 in total

1.  A llama-derived antibody for flu.

Authors:  Saheli Sadanand
Journal:  Nat Biotechnol       Date:  2019-01-03       Impact factor: 54.908

Review 2.  Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.

Authors:  John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims
Journal:  Antiviral Res       Date:  2019-04-08       Impact factor: 5.970

3.  Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.

Authors:  Maozhou He; Longfa Xu; Qingbing Zheng; Rui Zhu; Zhichao Yin; Zhenghui Zha; Yu Lin; Lisheng Yang; Yang Huang; Xiangzhong Ye; Shuxuan Li; Wangheng Hou; Yangtao Wu; Jinle Han; Dongxiao Liu; Zekai Li; Zhenqin Chen; Hai Yu; Yuqiong Que; Yingbin Wang; Xiaodong Yan; Jun Zhang; Ying Gu; Z Hong Zhou; Tong Cheng; Shaowei Li; Ningshao Xia
Journal:  Cell Host Microbe       Date:  2020-02-05       Impact factor: 21.023

Review 4.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

5.  A small-molecule fusion inhibitor of influenza virus is orally active in mice.

Authors:  Maria J P van Dongen; Rameshwar U Kadam; Jarek Juraszek; Edward Lawson; Boerries Brandenburg; Frederike Schmitz; Wim B G Schepens; Bart Stoops; Harry A van Diepen; Mandy Jongeneelen; Chan Tang; Jan Vermond; Alida van Eijgen-Obregoso Real; Sven Blokland; Divita Garg; Wenli Yu; Wouter Goutier; Ellen Lanckacker; Jaco M Klap; Daniëlle C G Peeters; Jin Wu; Christophe Buyck; Tim H M Jonckers; Dirk Roymans; Peter Roevens; Ronald Vogels; Wouter Koudstaal; Robert H E Friesen; Pierre Raboisson; Dashyant Dhanak; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2019-03-08       Impact factor: 47.728

6.  Structure and development of single domain antibodies as modules for therapeutics and diagnostics.

Authors:  Robert J Hoey; Hyeyoung Eom; James R Horn
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

7.  Mapping a Conformational Epitope of Hemagglutinin A Using Native Mass Spectrometry and Ultraviolet Photodissociation.

Authors:  M Rachel Mehaffey; Jiwon Lee; Jiwon Jung; Michael B Lanzillotti; Edwin E Escobar; Keith R Morgenstern; George Georgiou; Jennifer S Brodbelt
Journal:  Anal Chem       Date:  2020-08-12       Impact factor: 6.986

8.  Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies.

Authors:  Xueyong Zhu; Hannah L Turner; Shanshan Lang; Ryan McBride; Sandhya Bangaru; Iuliia M Gilchuk; Wenli Yu; James C Paulson; James E Crowe; Andrew B Ward; Ian A Wilson
Journal:  Cell Host Microbe       Date:  2019-11-19       Impact factor: 21.023

9.  Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2.

Authors:  Fred D Mast; Peter C Fridy; Natalia E Ketaren; Junjie Wang; Erica Y Jacobs; Jean Paul Olivier; Tanmoy Sanyal; Kelly R Molloy; Fabian Schmidt; Magda Rutkowska; Yiska Weisblum; Lucille M Rich; Elizabeth R Vanderwall; Nicolas Dambrauskas; Vladimir Vigdorovich; Sarah Keegan; Jacob B Jiler; Milana E Stein; Paul Dominic B Olinares; Theodora Hatziioannou; D Noah Sather; Jason S Debley; David Fenyö; Andrej Sali; Paul D Bieniasz; John D Aitchison; Brian T Chait; Michael P Rout
Journal:  bioRxiv       Date:  2021-04-10

10.  Designed proteins assemble antibodies into modular nanocages.

Authors:  Robby Divine; Ha V Dang; George Ueda; Jorge A Fallas; Ivan Vulovic; William Sheffler; Shally Saini; Yan Ting Zhao; Infencia Xavier Raj; Peter A Morawski; Madeleine F Jennewein; Leah J Homad; Yu-Hsin Wan; Marti R Tooley; Franziska Seeger; Ali Etemadi; Mitchell L Fahning; James Lazarovits; Alex Roederer; Alexandra C Walls; Lance Stewart; Mohammadali Mazloomi; Neil P King; Daniel J Campbell; Andrew T McGuire; Leonidas Stamatatos; Hannele Ruohola-Baker; Julie Mathieu; David Veesler; David Baker
Journal:  Science       Date:  2021-04-02       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.